Table 4 Characteristics of patients not achieving pCR
Patient | 1 | 2 |
|---|---|---|
Age | 49 | 56 |
cTNM/pyTNM | T2N0M0/pyT2N0M0 | T3N3M0/pyT3N3aM0 |
Histology | Ductal carcinoma | Ductal carcinoma |
Grade | 3 | 3 |
ER/PR/HER2 | Triple negative | Triple negative |
NACT regimen | FAC (1000 mg + 100 mg + 1000 mg) 3 cyclesCisplatin+Doxorubicin (140 mg + 110 mg) 3 cycles | Cisplatin+Doxorubicin (80 mg + 90 mg 4 cycles, 80 mg + 85 mg 2 cycles) |
Pre-tx tumor size | 45 mm | X (extensive, diffuse, difficult to evaluate the size) |
Post-tx tumor size | 25 mm | 65 mm |
Operation | Unilateral mastectomy | Bilateral mastectomy |
Lymphadenectomy | Yes | Yes |
Adjuvant CT | No | No |
Postoperative radiation | Yes | Yes |
Progression | No | Brain metastases, PFS 12 months, OS 15 months |